"We're looking at drugs that are already available -- are already on the market for people to treat one disease - and, based on an understanding of the way that drug works, we're now looking to see whether we can apply that drug to treat other diseases or symptoms."
In this podcast, The Michael J. Fox Foundation CEO Todd Sherer, PhD, discusses how drugs are chosen for so-called "repurposing" and why we still need to complete rigorous testing on these therapies.
"There's still a lot of work to do to make sure that the benefits would outweigh any risks of these medications," he says.
Hear more from Dr. Sherer on this topic in our next Third Thursdays Webinar on June 20 at 12 p.m. ET. Register today. Like what you hear? Subscribe to The Michael J. Fox Foundation Parkinson's Podcast in iTunes or your podcast mobile app. And please consider leaving us a rating on iTunes and sharing the series with your network.
